Article
Novartis succeeds where Alexion failed, coming up with a win for a prized asset in a rare kidney di
Rating:
0.0
Views:
118
Likes:
1
Library:
1
Three months after Alexion stumbled, Novartis declared another Phase II success for a drug it hopes can carve out significant new indications and potentially compete with Soliris. Novartis said today that iptacopan, also known as LNP023, successfully cut proteinuria — elevated protein levels in urine, an indicator of kidney inflammation
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value